Collectively, our studies emphasize the need to consider a maladaptive role of PERK in β cells in the pathogenesis of T1D and how inhibition of PERK might provide an opportunity, either alone or in combination with immune-modulating agents, for disease modification in T1D. This evidence concerns the gene EIF2AK3 and type 1 diabetes mellitus.